Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012;86(2):171-7.
doi: 10.1159/000339882. Epub 2012 Aug 14.

In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine

Yun Jeong Lim  1 , Tri M Phan, Elizabeth J Dial, David Y Graham, Lenard M Lichtenberger
Affiliations
Comparative Study

In vitro and in vivo protection against indomethacin-induced small intestinal injury by proton pump inhibitors, acid pump antagonists, or indomethacin-phosphatidylcholine

Yun Jeong Lim et al. Digestion. 2012.

Abstract

Background/aims: Proton pump inhibitors (PPIs) are widely used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcers. NSAIDs produce small intestinal injury and some PPIs have been reported to protect against NSAID-induced small bowel injury in rats. The aim of this study was to compare PPIs, revaprazan, and phosphatidylcholine-associated indomethacin (Indo-PC) for protection against indomethacin (Indo)-induced small bowel injury.

Methods: Rat intestinal epithelial cells (IEC-6) were pretreated with omeprazole, lansoprazole, or revaprazan prior to exposure to Indo or Indo-PC. Cell viability was assessed by methyl thiazolyl tetrazolium assay. Omeprazole, lansoprazole, or revaprazan was administered orally to rats prior to the vehicle or Indo. Indo-PC was administered alone. After 24 h, small intestinal erosions were counted; intestinal bleeding was assessed as the hemoglobin concentration of small intestinal fluid.

Results: Omeprazole, lansoprazole, and revaprazan did not protect against Indo-induced IEC-6 cell injury. Indo-PC was less damaging in vitro than Indo alone. In vivo, neither omeprazole nor lansoprazole protected against Indo-induced small bowel injury; however, revaprazan pretreatment and Indo-PC resulted in significantly fewer erosions (>50% reduction) or bleeding (>80% reduction).

Conclusion: PPIs showed no small bowel protective effect in vitro or in vivo. Revaprazan showed a small bowel protective effect in vivo, whereas Indo-PC was protective both in vitro and in vivo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
In vitro studies - Indo. (A) MTT assay showed that indomethacin decreased cell viability in a dose-dependent manner. (B) MTT assay showed that omeprazole, lansoprazole and revaprazan did not reverse the Indomethacin-induced reduction in intestinal cell viability.
Figure 2
Figure 2
In vitro studies – Indo-PC. (A) MTT assay showed Indo-PC at 1mM was less injurious than Indo alone. (B) Caspase-3/7 assay showed that Indo-PC induced less apoptosis than Indo alone. *=p<0.001 versus Control; #=p<0.001 versus Indo.
Figure 3
Figure 3
In vivo studies – lesions. (A) A 10 mg/kg dose of indomethacin produced punctate hemorrhagic spots and small punch-out lesions on the small intestine in rats. (B) Small intestinal lesion scores. Omeprazole and lansoprazole pretreatment did not alter the indomethacin-induced mucosal lesion score, while revaprazan pretreatment tended to reduce the lesion score (p=0.06). Indo-PC showed significantly fewer gross small intestine mucosal lesions than Indomethacin alone (p<0.05)*.
Figure 4
Figure 4
In vivo studies – bleeding. Intestinal fluid hemoglobin assay. Revaprazan-pretreatment group and Indomethacin-phosphatidylcholine (Indo-PC)-group had statistically significant decreased hemoglobin levels of the collected intestinal fluid compared to indomethacin alone (p<0.05)*. In contrast, omeprazole and lansoprazole did not reduce intestinal bleeding induced by indomethacin.
See this image and copyright information in PMC

References

    1. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am. 2010;39:433–464. - PubMed
    1. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59. - PubMed
    1. Maiden L, Thjodleifsson B, Seigal A, Bjarnason, Scott D, Birgisson S, Bjarnason S. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5:1040–1045. - PubMed
    1. Maiden L. Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J Gastroenterol. 2009;44:64–71. - PubMed
    1. Caunedo-Alvarez A, Gomez-Rodriguez BJ, Romero-Vazquez J, Arguelles-Arias F, Romero-Castro R, Garcia-Montes JM, Pellicer-Bautista FJ, Herrerias-Gutierrez JM. Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy. Rev Esp Enferm Dig. 2010;102:80–85. - PubMed

Publication types

MeSH terms